Online inquiry

IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11710MR)

This product GTTS-WQ11710MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11710MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15365MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ14670MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ9018MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ10586MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ9377MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ7516MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ9584MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ8893MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IGE25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW